Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• AlphaVbeta3 integrin plays a crucial role in tumor angiogenesis and is overexpressed in metastatic melanoma.
• Understanding the mechanism of action of targeted therapies is essential for improving cancer treatment.

Purpose of the Study:

• To investigate the mechanism of action of etaracizumab, a monoclonal antibody targeting alphaVbeta3, in patients with metastatic melanoma.
• To determine the optimal biologic dose of etaracizumab for achieving tumor saturation.

Main Methods:

• A dose-escalation study of etaracizumab in patients with metastatic melanoma.
• Primary endpoint: tumor saturation by etaracizumab assessed via immunohistochemical staining.
• Secondary endpoints: clinical benefit and biomarker analysis.

Main Results:

• Etaracizumab demonstrated dose-dependent tumor cell and vascular endothelial cell saturation, with 8 mg/kg showing the highest saturation.
• The 8 mg/kg dose was identified as the optimal biologic dose.
• No significant antiangiogenic or immunomodulatory effects were observed. Suppression of FAK was noted at higher doses but did not affect melanoma cell proliferation or apoptosis.

Conclusions:

• Etaracizumab effectively saturates tumor cells and vasculature in metastatic melanoma at the 8 mg/kg dose.
• While etaracizumab targets alphaVbeta3 and affects downstream signaling, it did not demonstrate significant clinical anti-proliferative or anti-apoptotic effects in this study.
• Further research may be needed to explore combination therapies or alternative mechanisms for etaracizumab in metastatic melanoma treatment.